2023 World Conference on Lung Cancer (Posters)-EP10.01. Clinical Features and Outcome Evaluation of Patients with Non-small-Cell Lung Cancer: A Single Center Study

EP10.01. Clinical Features and Outcome Evaluation of Patients with Non-small-Cell Lung Cancer: A Single Center Study - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the clinical features and outcome evaluation of patients with non-small-cell lung cancer (NSCLC) at a single center in Indonesia. The results showed that the clinical features of NSCLC in this population included male sex, non-smokers, mostly elderly individuals, adenocarcinoma pathology, and diagnosis at an advanced metastatic stage. Most subjects had epidermal growth factor receptor (EGFR) mutation and underwent anti-EGFR treatment. The evaluation after the first 6 months showed mostly favorable response.<br /><br />Lung cancer is the most common new cancer cases in men and the third most common in women in Indonesia, and it is the leading cause of cancer death in the country. NSCLC accounts for 80-85% of lung cancer cases.<br /><br />The study included 41 newly diagnosed NSCLC patients, with 41.4% of them being females. The median age of the subjects was 60 years. Adenocarcinoma was the most common pathology, present in 73.2% of the subjects, followed by squamous cell carcinoma in 12.2% of the subjects. Non-smokers accounted for 51.2% of the subjects, and 63.4% were in the metastatic stage. EGFR mutation was present in 63.2% of the subjects, with 7 of them having point mutations in exon 21 or deletions in exon 19. There were no subjects with ALK rearrangement, and 12.2% had PD-L1 mutation. Platinum-based chemotherapy was given to 41.5% of the subjects, while 43.9% received anti-EGFR therapy with erlotinib or gefitinib. After 6 months of evaluation using CT scan, 65.9% of the subjects showed minimally stable disease, while only 3 subjects showed progression.<br /><br />In conclusion, this study provides insights into the clinical features and outcomes of NSCLC patients in Indonesia. The majority of the patients had EGFR mutation and underwent anti-EGFR treatment, with most showing a favorable response after 6 months. Further research can focus on evaluating clinical response, progression-free survival, and overall survival in EGFR-mutation NSCLC.

Asset Subtitle

Andree Kurniawan

Meta Tag

Speaker Andree Kurniawan

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

non-small-cell lung cancer

clinical features

outcome evaluation

Indonesia

adenocarcinoma pathology

EGFR mutation

anti-EGFR treatment

favorable response

platinum-based chemotherapy

CT scan